

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

28 Jun 2026

### Comparative efficacy of unified protocol of transdiagnostic psychotherapy, metacognitive therapy, and mirtazapine treatment in the frequency and severity of physical symptoms, psychological symptoms, and quality of life in functional dyspepsia disorder

#### Protocol summary

Functional dyspepsia symptoms; cortisol, serotonin; depression and anxiety

#### Study aim

Comparison the efficacy of psychotherapy between pharmacotherapy in patients with functional dyspepsia

#### Design

Randomized control trial consisted of parallel groups, single blind

#### Settings and conduct

This research conducted in Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, in a randomized clinical trial with single-blinding of patients.

#### Participants/Inclusion and exclusion criteria

Inclusion criteria: having functional dyspepsia without comorbid disease such as IBS or other digestive disease; not having any variety of chronic somatic diseases; no simultaneous use of other psychiatric drugs; no dependency on or abusing substance; partial adherence to diet and exercise; absence of severe psychiatric disorders; age range between 18 and 55 years old; reading and writing skills. Exclusion criteria: unwillingness to participate in the research for any reason Inability of the patient to access the medical center; chronic physical impairment or physical inability; severe mental disorder; substance abuse or dependence; patients need to take any medicine other than the prescribed drugs in the study during the study.

#### Intervention groups

Unified protocol transdiagnostic psychotherapy consisted of 12, 45-minute individual treatment sessions based on Barlow protocol to target key aspects of emotional processing and regulation of emotional experiences, metacognitive therapy 10-session 45-minute treatment based on the Adrian Wells protocol approach to metacognitive therapy focused on anxiety protocol, mirtazapine 7.5 ml per day over 12 weeks.

#### Main outcome variables

#### General information

##### Reason for update

##### Acronym

UP, MCT,

##### IRCT registration information

IRCT registration number: **IRCT20190312043036N2**

Registration date: **2021-05-07, 1400/02/17**

Registration timing: **prospective**

Last update: **2021-05-07, 1400/02/17**

Update count: **0**

##### Registration date

2021-05-07, 1400/02/17

##### Registrant information

##### Name

Sepideh Batebi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 2610 1204

##### Email address

s.batebi@sbmu.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2021-05-22, 1400/03/01

##### Expected recruitment end date

2023-02-20, 1401/12/01

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Comparative efficacy of unified protocol of transdiagnostic psychotherapy, metacognitive therapy, and mirtazapine treatment in the frequency and severity of physical symptoms, psychological symptoms, and quality of life in functional dyspepsia disorder

**Public title**

Comparative efficacy of unified protocol of transdiagnostic psychotherapy, metacognitive therapy, and mirtazapine in functional dyspepsia disorder

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Suffering functional dyspepsia without comorbid diseases such as IBS or other digestive diseases if IBS was comorbid, the onset of functional dyspepsia symptoms would be prior to IBS Not having any variety of chronic somatic diseases No simultaneous use of other psychiatric drugs No dependency on or abusing substance Partial adherence to diet and exercise Absence of severe psychiatric disorders Age range between 18 and 55 Having reading and writing skills 6 months lasted from the definite diagnosis of functional dyspepsia for all patients All patients had not taken any psychiatric drug and psychotherapy during the last 3 months ago 80-90% adherence to the targeted treatments and treatment as usual in any groups

**Exclusion criteria:**

Unwillingness to participate in the research for any reason Inability of the patient to access the medical center Having chronic physical impairment or physical inability Having a severe mental disorder Substance use or dependence Patients need to take any medicine other than the prescribed drugs in the study during the study Infected to H-pylori Being pregnant Having any physiopathology in Endoscopy Having any severe and intolerable side effects Patients need to take any medicine other than the prescribed drugs in the study during the study

**Age**

From **18 years** old to **55 years** old

**Gender**

Both

**Phase**

N/A

**Groups that have been masked**

- Participant

**Sample size**

Target sample size: **220**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

At first, the available sample was selected from those who referred to the gastroenterology clinic of Taleghani Hospital and the affiliated centers. Finally, based on the simple random sampling, patients refer in odd days from 8 to 13 hour recruited in the up group, patients refer in odd days from 14- 19 hours recruited the metacognitive group, patients patient refer in even days from 8 to 13 hour recruited in mirtazapine treated group, patients refer in even days from 14- 19 hours recruited the placebo group

**Blinding (investigator's opinion)**

Single blinded

**Blinding description**

All the patients were single-blinded according to the treatments offering to them

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Shahid Beheshti University of Medical Sciences

**Street address**

Shahid Beheshti University of Medical Sciences, Velenjak St.

**City**

Tehran

**Province**

Tehran

**Postal code**

1985717443

**Approval date**

2021-02-15, 1399/11/27

**Ethics committee reference number**

IR.SBMU.RIGLD.REC.1399.066

**Health conditions studied****1****Description of health condition studied**

Functional dyspepsia

**ICD-10 code**

K30

**ICD-10 code description**

Functional dyspepsia

**Primary outcomes**

## 1

### **Description**

Symptoms of functional dyspepsia

### **Timepoint**

Pre test, post test and follow up

### **Method of measurement**

Leeds dyspepsia questionnaire and clinical interview based on Rome IV

## 2

### **Description**

Depression

### **Timepoint**

Pre test, post test and follow up three months after treatment

### **Method of measurement**

Hamilton depression questionnaire

## 3

### **Description**

Anxiety

### **Timepoint**

Pre test, post test and follow up three months after treatment

### **Method of measurement**

Hamilton anxiety questionnaire

## **Secondary outcomes**

## 1

### **Description**

Quality of life

### **Timepoint**

Pre test, post test and follow up three months after treatment

### **Method of measurement**

Nepean dyspepsia index for quality of life

## 2

### **Description**

Emotional regulation

### **Timepoint**

Pre test, post test and follow up three months after treatment

### **Method of measurement**

Questionnaire for difficulty in emotional regulation

## 3

### **Description**

Emotional processing

### **Timepoint**

Pre test, post test and follow up three months after treatment

### **Method of measurement**

Baker's emotional processing questionnaire

## **Intervention groups**

## 1

### **Description**

Intervention group 1: metacognitive therapy, 10-session 45-minute treatment based on the Adrian Wells protocol approach to metacognitive therapy focused on anxiety protocol; First session: Formulation; Second session: Mindfulness training; Third to sixth sessions: Working on negative metacognitive beliefs; sessions 7 and 8: Challenging Positive metacognitive beliefs; sessions 9 and 10: New processing style training and relapse prevention training with common treatment: omeprazole and domperidone 25 mg for 10 weeks, once daily (made by Sobhan company) plus adhering to recommended diet and regular exercise.

### **Category**

Behavior

## 2

### **Description**

Intervention group: the second intervention: unified protocol of transdiagnostic treatment, 12 sessions 45 minutes psychotherapy based on the manual based approach of unified transdiagnostic psychotherapy by David Barlow, the aims of the session: 1: increasing present-focused emotion awareness, 2: increasing cognitive flexibility, 3: identifying and preventing patterns of emotion avoidance and maladaptive emotion-driven behaviors (EDBs), 4: increasing awareness and tolerance of emotion-related physical sensations, and 5: interoceptive and situation-based emotion-focused exposure.

### **Category**

Behavior

## 3

### **Description**

Intervention group 3: 7.5 mg Mirtazapine for 12 weeks, once daily, Sobhan manufacturer with usual treatment: omeprazole 20 mg and domperidone 10 mg for 10 weeks, once daily, Sobhan manufacturer, and adhering to recommended diet and regular exercise.

### **Category**

Treatment - Drugs

## 4

### **Description**

Control group: usual treatment by omeprazole (20 mg, once daily, Sobhan Darou) and domperidone ( motidon, 10 mg, once daily, Abidi co.) for 12 weeks, and recommended diet and regular exercise.

### **Category**

Placebo

## **Recruitment centers**

## 1

### Recruitment center

**Name of recruitment center**

Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Dr.Mohamad Reza Zali

**Street address**

Shahid Beheshti university of medical science, Velenjak st.

**City**

tehran

**Province**

Tehran

**Postal code**

1985717413

**Phone**

+98 21 2243 2521

**Fax****Email**

info@sbmu.ac.ir

**Web page address**

http://rigld.sbmu.ac.ir

### Sponsors / Funding sources

## 1

#### Sponsor

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Dr. Afshin Zarghi

**Street address**

Shahid Beheshti University of Medical Sciences

**City**

tehran

**Province**

Tehran

**Postal code**

1985717443

**Phone**

+98 21 23871

**Email**

info@sbmu.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

No

**Title of funding source**

Shahid Beheshti University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin****Type of organization providing the funding**

Academic

### Person responsible for general inquiries

**Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Amir Sadeghi

**Position**

Assistant professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Physical Medicine

**Street address**

Shahid Arababi Street Next to Ayatollah Taleghan Hospital, Yemen St. Martyr Chamran Highway, Tehran

**City**

Tehran

**Province**

Tehran

**Postal code**

1985717443

**Phone**

+98 21 2243 2521

**Email**

sepsiedu@gmail.com

### Person responsible for scientific inquiries

**Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Sepideh Batebi

**Position**

assistant professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Psychology

**Street address**

Arabi st. Velenjack

**City**

Tehran

**Province**

Tehran

**Postal code**

1985717443

**Phone**

+98 21 2243 2521

**Email**

s.batebi@sbmu.ac.ir

### Person responsible for updating data

**Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Sepideh Batebi

**Position**

assistant professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Psychology

**Street address**

Arabi St. Velenjack

**City**

tehran

**Province**

Tehran

**Postal code**

1985717443

**Phone**

+98 21 2243 2521

**Email**

s.batebi@sbmu.ac.ir

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Not applicable

**Data Dictionary**

Not applicable

**Title and more details about the data/document**

results, tables and treatment protocol

**When the data will become available and for how long**

6 months after publication

**To whom data/document is available**

Qualified applicants (graduates of medical, specialty and fellowship, psychiatrists, clinical and health psychologists)

**Under which criteria data/document could be used**

Repeated measure analysis

**From where data/document is obtainable**

Sepideh Batebi s.batebi@sbmu.ac.ir

**What processes are involved for a request to access data/document**

The applicants must first submit their application by an academic email to the correspondent, and then, the requests will be checked within one week and if approved the data will be sent.

**Comments**